Processing

Please wait...

Settings

Settings

Goto Application

1. EP3268366 - (INDAZOL-4-YL)HEXAHYDROPYRROLOPYRROLONES AND METHOD OF USE

Office European Patent Office
Application Number 16710656
Application Date 14.03.2016
Publication Number 3268366
Publication Date 17.01.2018
Publication Kind A1
IPC
C07D 487/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
487Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/-C07D477/183
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
A61K 31/416
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
4151,2-Diazoles
416condensed with carbocyclic ring systems, e.g. indazole
A61P 25/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
CPC
C07D 487/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
487Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
Applicants ABBVIE INC
Inventors DAANEN JEROME
DEGOEY DAVID A
FROST JENNIFER M
JINKERSON TAMMIE
LATSHAW STEVE
SHI LEI
Designated States
Priority Data 201562132953 13.03.2015 US
2016022262 14.03.2016 US
Title
(DE) (INDAZOL-4-YL) HEXAHYDROPYRROLOPYRROLEN UND VERWENDUNGSVERFAHREN
(EN) (INDAZOL-4-YL)HEXAHYDROPYRROLOPYRROLONES AND METHOD OF USE
(FR) (INDAZOL-4-YL)HEXAHYDROPYRROLOPYRROLONES ET LEUR MÉTHODE D'UTILISATION
Abstract
(EN)
Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein GAr, L1, Z1and Z2are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by voltage-gated sodium channels, e.g., Nayl.7 and/or Nayl.8. Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions for the treatment of pain.

(FR)
L'invention concerne des composés de formule (I) et des sels, esters, amides, ou formes radiomarquées pharmaceutiquement acceptables de ceux-ci. Dans la formule, GAr, L1, Z1 et Z2 ont la signification indiquée dans la description. Lesdits composés sont utiles pour traiter des états ou troubles dont la prévention est assurée par ou qui sont atténués par les canaux sodiques dépendants du potentiel, par exemple, Nav1.7 et/ou Nav1.8. L'invention concerne également des procédés pour la fabrication desdits composés. L'invention concerne en outre des compositions pharmaceutiques des composés de formule (I), et des méthodes d'utilisation des composés et compositions pour le traitement de la douleur.